5-Amino-1MQ
5-amino-1-methylquinolinium (selective NNMT inhibitor; small molecule, not a peptide)
Selective NNMT-inhibitor research focused on cellular energy balance and metabolic function.
Route
Subcutaneous in the community research protocol
Common format
50 mg vial
Research focus
NNMT inhibition
Evidence level
Preclinical Evidence
Typical cycle
4–8 weeks
Fat Loss5-Amino-1MQ in 30 seconds
Atlas Fast ReadWhat it is
5-amino-1-methylquinolinium (selective NNMT inhibitor; small molecule, not a peptide)
Why people care
Selective NNMT-inhibitor research focused on cellular energy balance and metabolic function.
Human evidence
Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.
Biggest misconception
Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.
Bottom line
5-Amino-1MQ is an intriguing NNMT inhibitor, but it is a preclinical small molecule—not a human-proven fat-loss peptide.
Overview
What is 5-Amino-1MQ?
5-Amino-1MQ is a selective NNMT inhibitor often grouped with peptide protocols, but chemically it is a small molecule rather than a peptide. Atlas places it in the metabolic/fat-loss section because most interest centers on adipose metabolism, NAD-related biology, and body-composition research.
Developed from modern nicotinamide N-methyltransferase (NNMT) inhibitor research after NNMT was linked to adipose metabolism and obesity. Most published work on 5-Amino-1MQ itself dates from the late 2010s onward.
Mechanism
How it works
Inhibits nicotinamide N-methyltransferase (NNMT), which may spare nicotinamide and methyl donors for NAD-related metabolism. In animal models, NNMT inhibition shifts adipose energy handling and is associated with higher NAD/SIRT1 signaling.
Research areas
Evidence
What does the evidence actually say?
The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.
Preclinical Evidence
Limited Human Evidence
Strong Human Evidence
Human evidence
Preclinical evidence
Knowledge gaps
Protocol
Research protocol
Dose
Frequency
Timing
Route
Cycle length
Reconstitution
Storage
Monitoring
Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.
Safety
Safety, side effects, and precautions
Side effects
Contraindications
Interactions
Stacks
Common stacks
5-Amino-1MQ alone
NNMT inhibition is still preclinical; stacking with other metabolic agents would add uncertainty rather than evidence.
No validated human combination data.
Questions
FAQ
References
Sources
- Primary studySelective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
- Primary studyReduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice
- Primary literature indexPubMed literature search: 5-Amino-1MQ
- Clinical trials indexClinicalTrials.gov search: 5-Amino-1MQ
Atlas
The Atlas verdict
5-Amino-1MQ is an intriguing NNMT inhibitor, but it is a preclinical small molecule—not a human-proven fat-loss peptide. Atlas would focus on the metabolic mechanism while being explicit that human efficacy, dosing and safety remain unknown.
More in Fat Loss
Fat Loss
AOD-9604
Modified growth-hormone fragment studied for lipolysis and fat-metabolism effects without targeting IGF-1.
Read guideFat Loss
Cagrilintide
Long-acting amylin-analog research focused on appetite regulation, satiety, and body-weight reduction.
Read guideFat Loss
Cagrilintide + Semaglutide
Dual amylin and GLP-1 pathway research aimed at appetite control and significant weight reduction.
Read guide